Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network

Clin Infect Dis. 2020 Dec 17;71(10):e714-e717. doi: 10.1093/cid/ciaa488.


This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929.

Keywords: HIV; cobicistat; elvitegravir; pharmacokinetics; pregnancy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Anti-Retroviral Agents / therapeutic use
  • Female
  • HIV Infections* / drug therapy
  • Humans
  • Pregnancy
  • Pregnancy Complications, Infectious* / drug therapy
  • Pregnancy Trimester, Third
  • Pregnant Women
  • Quinolones


  • Anti-HIV Agents
  • Anti-Retroviral Agents
  • Quinolones
  • elvitegravir

Associated data